Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium.

Correspondence is also little doubt that technologic and human capabilities will continue to improve and that improvements in patients’ outcomes will follow. The point of our editorial was not to argue against research and innovation, quite to the contrary. Our view is simply that the lessons of the worldwide 2009 infl uenza A(H1N1) epidemic do not support a costly, nationwide investment in new ECMO programs. We believe that the physiologic boundaries that defi ne current treatment space do warrant more careful examination and that ECMO has a place as a research tool in that endeavor.